NOVO NORDISK INC.: Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy in a pill*) and obesity pipeline at ObesityWeek 2025

New data from OASIS 4 on oral semaglutide 25 mg to reveal insights on cardiometabolic health among adults with obesity or overweight Additional trial insights ...
GEN - Genetic Engineering and Biotechnology News

2025 Proteomics Breakthroughs

To explore the latest breakthroughs in proteomics, GEN spoke with five companies at the forefront of proteomic innovation.
The Cardiology Advisor

Higher Semaglutide Dose Demonstrates Superior Efficacy in Obesity, T2D

Higher semaglutide dose of 7.2 mg was associated with superior weight loss and comparable safety outcomes among patients with obesity.
The Victoria Advocate

STEP 9 results, published in NEJM, demonstrated semaglutide reduced knee osteoarthritis-related pain in people with obesity

STEP 9 was a randomized, double-blind, placebo-controlled multicenter trial designed to evaluate the efficacy of semaglutide 2.4 mg versus placebo as an adjunct to lifestyle modifications (counseling ...
Nasdaq

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of ...